- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04008524
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
August 2, 2022 updated by: wang, jianxiang, Institute of Hematology & Blood Diseases Hospital
This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies.
These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria.
This project is designed to meet the urgent clinical needs of individual patients.
Study Overview
Status
Available
Intervention / Treatment
Study Type
Expanded Access
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ying Wang, Dr.
- Phone Number: +86-22-23909278
- Email: wangying1@ihcams.ac.cn
Study Locations
-
-
-
Tianjin, China, 300020
- Available
- Institute of Hematology & Blood Diseases Hospital
-
Principal Investigator:
- Jianxiang Wang, Dr.
-
Contact:
- Ying Wang, Dr.
- Phone Number: 86-22-23909278
- Email: wangying1@ihcams.ac.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients suffering from a hematological malignancy that is severely life-threatening or seriously affects the patient's quality of life and has no effective treatment available, who not meet the inclusion/exclusion criteria for other clinical trials in the process of subject recruitment, or who are unable to obtain other study drugs or participate in clinical studies/trials for some reason (regional or time restriction, etc., or the recruitment of subjects for clinical studies/trials has ended but the drug has not yet been approved for marketing in China);
Patients who are definitely diagnosed with the corresponding target-positive relapsed and refractory hematological malignancies, including but not limited to the following circumstances:
- Patients who do not meet the inclusion/exclusion criteria for existing clinical trials, such as age <18 years, ECOG >1, extramedullary recurrence, persistent or repeatedly positive for minimal residual disease;
- Patients who have relapsed after remission following CAR-T cell therapy, and are expected as judged by the investigator to benefit more from re-use of the same cell or sequential use of other CAR-T cells compared with the risk;
- The quantity of CAR-T cells produced does not meet the release criteria of production quality inspection, but is >0.1× 106/kg CAR positive T cells, and the investigator judges that the expected benefit of cell infusion is greater than the risk;
- The disease progresses rapidly after cell collection and before infusion, and the investigator judges that the expected benefit of cell infusion is greater than the risk;
- Patients who have relapsed after autologous/heterogeneous hematopoietic stem cell transplantation (including those positive for minimal residual disease);
- Other circumstances where the investigator judges that the expected benefit of cell infusion is greater than the risk.
- Patients with appropriate bone marrow reserve: such as lymphocyte count >0.3×109/L;
- Patients with proper heart, lung, liver, kidney and coagulation functions;
- The selected patients or their legal representatives voluntarily sign the informed consent form.
Exclusion Criteria:
- Patients who are positive for any of HIV antibody, TP antibody, HBsAg and HCV antibody.
- Patients with a history of epilepsy or other central nervous system diseases.
- Patients with evidence of currently uncontrollable serious active infections (e.g., sepsis, bacteremia, fungemia, viremia, etc.).
- Patients with other conditions making the patients unsuitable for receiving cell therapy as judged by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
July 1, 2019
First Submitted That Met QC Criteria
July 1, 2019
First Posted (Actual)
July 5, 2019
Study Record Updates
Last Update Posted (Actual)
August 3, 2022
Last Update Submitted That Met QC Criteria
August 2, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HY001502
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed and Refractory Hematological Malignancies
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory Hematological MalignanciesChina
-
CASI Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada
-
Shandong UniversityJuventas Cell Therapy Ltd.UnknownRelapsed or Refractory Hematological MalignanciesChina
-
He HuangYake Biotechnology Ltd.RecruitingRelapsed and Refractory | Lymphoid Hematological MalignanciesChina
-
The Affiliated People's Hospital of Ningbo UniversityUTC Therapeutics Inc.RecruitingLymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological MalignanciesChina
-
Acrotech Biopharma Inc.Axis Clinicals LimitedTerminatedRelapsed/Refractory Solid Tumors/Hematological MalignanciesUnited States
-
Curon Biopharmaceutical (Australia) Co Pty LtdNovotech (Australia) Pty LimitedTerminatedRelapsed Lymphoid Malignancies | Refractory Lymphoid MalignanciesAustralia
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory B-Cell MalignanciesChina, Australia
-
Minghui Pharmaceutical (Shanghai) LTDRecruitingRelapsed/Refractory B-cell MalignanciesChina
-
Gilead SciencesCompletedRelapsed/Refractory B-cell MalignanciesFrance, United Kingdom
Clinical Trials on CAR-T cells
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingInfectious Diseases | Hematological MalignanciesChina